

Francois Le Loarer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1716775/publications.pdf>

Version: 2024-02-01

54
papers

2,667
citations

257101

24
h-index

197535

49
g-index

64
all docs

64
docs citations

64
times ranked

2976
citing authors

#	ARTICLE	IF	CITATIONS
1	SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. <i>Nature Genetics</i> , 2015, 47, 1200-1205.	9.4	252
2	Transcriptomic definition of molecular subgroups of small round cell sarcomas. <i>Journal of Pathology</i> , 2018, 245, 29-40.	2.1	235
3	Surgery in reference centers improves survival of sarcoma patients: a nationwide study. <i>Annals of Oncology</i> , 2019, 30, 1143-1153.	0.6	191
4	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. <i>Nature Cancer</i> , 2021, 2, 794-802.	5.7	173
5	Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. <i>BMC Medicine</i> , 2017, 15, 78.	2.3	143
6	Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. <i>PLoS ONE</i> , 2021, 16, e0246958.	1.1	131
7	SMARCA4-deficient Thoracic Sarcomas. <i>American Journal of Surgical Pathology</i> , 2019, 43, 455-465.	2.1	123
8	Consistent <i>SMARCB1</i> homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 475-486.	1.5	120
9	Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. <i>European Journal of Cancer</i> , 2019, 119, 151-157.	1.3	103
10	The current landscape of rhabdomyosarcomas: an update. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 97-108.	1.4	97
11	Clinicopathologic Features of CIC-NUTM1 Sarcomas, a New Molecular Variant of the Family of CIC-Fused Sarcomas. <i>American Journal of Surgical Pathology</i> , 2019, 43, 268-276.	2.1	96
12	Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. <i>Nature Medicine</i> , 2022, 28, 1199-1206.	15.2	88
13	A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. <i>Modern Pathology</i> , 2020, 33, 404-419.	2.9	80
14	T ₂ -based MRI Delta ² radiomics improve response prediction in soft-tissue sarcomas treated by neoadjuvant chemotherapy. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 497-510.	1.9	74
15	Clinicopathologic and Molecular Features of a Series of 41 Biphenotypic Sinonasal Sarcomas Expanding Their Molecular Spectrum. <i>American Journal of Surgical Pathology</i> , 2019, 43, 747-754.	2.1	65
16	Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions. <i>Modern Pathology</i> , 2018, 31, 1683-1693.	2.9	56
17	Effect of decalcification protocols on immunohistochemistry and molecular analyses of bone samples. <i>Modern Pathology</i> , 2020, 33, 1505-1517.	2.9	44
18	Update on Families of Round Cell Sarcomas Other than Classical Ewing Sarcomas. <i>Surgical Pathology Clinics</i> , 2017, 10, 587-620.	0.7	43

#	ARTICLE	IF	CITATIONS
19	BAFfling pathologies: Alterations of BAF complexes in cancer. <i>Cancer Letters</i> , 2018, 419, 266-279.	3.2	38
20	NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker. <i>Modern Pathology</i> , 2020, 33, 1930-1944.	2.9	38
21	SRF-FOXO1 and SRF-NCOA1 Fusion Genes Delineate a Distinctive Subset of Well-differentiated Rhabdomyosarcoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 607-616.	2.1	37
22	Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients. <i>European Radiology</i> , 2019, 29, 4730-4741.	2.3	33
23	Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. <i>Annals of Oncology</i> , 2021, 32, 1381-1390.	0.6	33
24	Pleomorphic Sarcomas. <i>Surgical Pathology Clinics</i> , 2019, 12, 63-105.	0.7	26
25	Superficial CD34-positive fibroblastic tumor and <i>PRDM10</i> -rearranged soft tissue tumor are overlapping entities: a comprehensive study of 20 cases. <i>Histopathology</i> , 2021, 79, 810-825.	1.6	26
26	The combination of radiotherapy and ALK inhibitors is effective in the treatment of intraosseous rhabdomyosarcoma with <i>FUS</i> - <i>TFCP2</i> fusion transcript. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28185.	0.8	24
27	Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas. <i>Journal of Hematology and Oncology</i> , 2017, 10, 84.	6.9	23
28	Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. <i>Annals of Oncology</i> , 2022, 33, 1041-1051.	0.6	22
29	The SS18-SSX Antibody Has Perfect Specificity for the SS18-SSX Fusion Protein. <i>American Journal of Surgical Pathology</i> , 2021, 45, 582-584.	2.1	19
30	Wholistic approach: Transcriptomic analysis and beyond using archival material for molecular diagnosis. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 382-393.	1.5	18
31	ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status. <i>Scientific Reports</i> , 2020, 10, 7488.	1.6	16
32	MRI assessment of surrounding tissues in soft-tissue sarcoma during neoadjuvant chemotherapy can help predicting response and prognosis. <i>European Journal of Radiology</i> , 2018, 109, 178-187.	1.2	14
33	Determinants of the access to remote specialised services provided by national sarcoma reference centres. <i>BMC Cancer</i> , 2021, 21, 631.	1.1	14
34	SWI/SNF-deficient thoraco-pulmonary neoplasms. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 183-194.	1.0	14
35	Advances in the classification of round cell sarcomas. <i>Histopathology</i> , 2022, 80, 33-53.	1.6	14
36	<i>MDM4</i> amplification in a case of de-differentiated liposarcoma and <i>in-silico</i> data supporting an oncogenic event alternative to <i>MDM2</i> amplification in a subset of cases. <i>Histopathology</i> , 2017, 71, 1019-1023.	1.6	13

#	ARTICLE	IF	CITATIONS
37	High-grade soft-tissue sarcoma: optimizing injection improves MRI evaluation of tumor response. <i>European Radiology</i> , 2019, 29, 545-555.	2.3	13
38	Recurrent YAP1::MAML2 fusions in nodular necrotizing variants of myxoinflammatory fibroblastic sarcoma: a comprehensive study of 7 cases. <i>Modern Pathology</i> , 2022, 35, 1398-1404.	2.9	13
39	Recurrent novel THBS1-ADGRF5 gene fusion in a new tumor subtype Acral FibroChondroMyxoid Tumors. <i>Modern Pathology</i> , 2020, 33, 1360-1368.	2.9	12
40	Infantile Rhabdomyosarcomas With VGLL2 Rearrangement Are Not Always an Indolent Disease. <i>American Journal of Surgical Pathology</i> , 2021, 45, 854-867.	2.1	12
41	Soft Tissue Sarcomas: The Role of Quantitative MRI in Treatment Response Evaluation. <i>Academic Radiology</i> , 2022, 29, 1065-1084.	1.3	10
42	Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2022, 33, 1084-1085.	0.6	10
43	Specific and Sensitive Diagnosis of BCOR-ITD in Various Cancers by Digital PCR. <i>Frontiers in Oncology</i> , 2021, 11, 645512.	1.3	8
44	Clinicopathologic and Molecular Study of Hybrid Nerve Sheath Tumors Reveals Their Common Association With Fusions Involving VGLL3. <i>American Journal of Surgical Pathology</i> , 2022, 46, 591-602.	2.1	8
45	Abnormal vascularization of soft-tissue sarcomas on conventional MRI: Diagnostic and prognostic values. <i>European Journal of Radiology</i> , 2019, 117, 112-119.	1.2	6
46	Thyroid-like follicular renal cell carcinoma with sarcomatoid differentiation and an aggressive clinical course: a case report confirming the presence of the <i>EWSR1::PATZ1</i> fusion gene. <i>Histopathology</i> , 2022, 80, 745-748.	1.6	6
47	New developments in the pathology and molecular biology of retroperitoneal sarcomas. <i>European Journal of Surgical Oncology</i> , 2023, 49, 1053-1060.	0.5	6
48	Novel <i>EWSR1::UBP1</i> fusion expands the spectrum of spindle cell rhabdomyosarcomas. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 200-205.	1.5	6
49	No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks™ Outcome?. <i>Cancers</i> , 2022, 14, 2620.	1.7	4
50	Implementing a Machine Learning Strategy to Predict Pathologic Response in Patients With Soft Tissue Sarcomas Treated With Neoadjuvant Chemotherapy. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 958-972.	1.0	3
51	Natural speed of growth of untreated soft-tissue sarcomas: A dimension-based imaging analysis. <i>European Journal of Radiology</i> , 2022, 146, 110082.	1.2	3
52	Update on Mesenchymal Lesions of the Lower Female Genital Tract. <i>Surgical Pathology Clinics</i> , 2022, 15, 341-367.	0.7	2
53	SMARCA4-Deficient Sarcoma. <i>Encyclopedia of Pathology</i> , 2020, , 1-8.	0.0	0
54	Rhabdoid Tumor, Soft Tissue. <i>Encyclopedia of Pathology</i> , 2020, , 1-9.	0.0	0